age-related macular degeneration
Ophthalmology · 2007–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| aflibercept Biosimilar to Eylea for the same indications (not specified in detail in this PSD, as it is a Category 3 biosimilar submission). | Jul 2025 | Recommended | none received |
| aflibercept Treatment of subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD), specifically neovascular age-related macular… | Nov 2024 | Recommended with restriction | none received |
| brolucizumab Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD). | Jul 2020 | Recommended with restriction | input received |
| brolucizumab Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD). | Nov 2019 | Not recommended | input received Macular Disease Foundation Australia |
| aflibercept Initial and continuing treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein… | Mar 2012 | Recommended with restriction | unclear |
| aflibercept Initial and continuing treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (wet AMD), as diagnosed by fluorescein… | Mar 2012 | Recommended with restriction | unclear |
| ranibizumab Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), administered by intravitreal injection. | Mar 2007 | Recommended with restriction | no section in document |
| ranibizumab Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD). The indication encompasses predominantly classic… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Macular Disease Foundation Australia
What the PBS pays
$599M in government benefit over 2024–25, across 620,356 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| aflibercept | $506.1M |
| ranibizumab | $91.6M |
| brolucizumab | $1.5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| ranibizumab and pegaptanibRanibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | recommended | 2008-08 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.